Precision medicine in pediatric solid cancers.

[1]  P. Houghton,et al.  In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium , 2020, Pediatric blood & cancer.

[2]  M. Snuderl,et al.  The Role of Liquid Biopsies in Pediatric Brain Tumors. , 2020, Journal of neuropathology and experimental neurology.

[3]  Dung-Fang Lee,et al.  Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas , 2020, Theranostics.

[4]  J. Braithwaite,et al.  Development of an implementation and evaluation strategy for the Australian ‘Zero Childhood Cancer’ (Zero) Program: a study protocol , 2020, BMJ Open.

[5]  M. Prados,et al.  Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002) , 2020, Oncotarget.

[6]  Y. Jamin,et al.  Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma , 2020, Journal of Experimental & Clinical Cancer Research.

[7]  Milind Kamkolkar.  First drug approved for neurofibromas is a MEK inhibitor , 2020, Nature Biotechnology.

[8]  D. Viskochil,et al.  The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities , 2020, The oncologist.

[9]  A. Italiano.  Targeting epigenetics in sarcomas through EZH2 inhibition , 2020, Journal of Hematology & Oncology.

[10]  Jennifer L. Hadley,et al.  Germline Elongator mutations in Sonic Hedgehog medulloblastoma , 2020, Nature.

[11]  C. Hawkins,et al.  Pediatric low-grade glioma in the era of molecular diagnostics , 2020, Acta Neuropathologica Communications.

[12]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[13]  P. Sorensen,et al.  Ewing Sarcoma , 2020, Sarcomas.

[14]  Steven J. M. Jones,et al.  Pan-cancer analysis of whole genomes , 2020, Nature.

[15]  C. Pui,et al.  The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead , 2020, Clinical pharmacology and therapeutics.

[16]  B. Geoerger,et al.  Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study , 2019, Clinical Cancer Research.

[17]  Chuan He,et al.  Progress toward liquid biopsies in pediatric solid tumors , 2019, Cancer and Metastasis Reviews.

[18]  N. Jabado,et al.  A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01 , 2019, BMC Cancer.

[19]  T. Kirchner,et al.  Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies , 2019, Cancer and Metastasis Reviews.

[20]  B. Al-Lazikani,et al.  A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations , 2019, European journal of cancer.

[21]  Sara M. Federico,et al.  A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma , 2019, Clinical Cancer Research.

[22]  W. Młynarski,et al.  Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain , 2019, Front. Oncol..

[23]  Arun K. Ramani,et al.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.

[24]  C. Pratilas,et al.  A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors , 2019, Clinical Cancer Research.

[25]  S. Plon,et al.  Genetic Predisposition to Childhood Cancer in the Genomic Era. , 2019, Annual review of genomics and human genetics.

[26]  M. Eguchi,et al.  Early detection of the PAX3‐FOXO1 fusion gene in circulating tumor‐derived DNA in a case of alveolar rhabdomyosarcoma , 2019, Genes, chromosomes & cancer.

[27]  James R. Anderson,et al.  Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group , 2019, Cancer.

[28]  David T. W. Jones,et al.  Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours , 2019, Nature Reviews Cancer.

[29]  David T. W. Jones,et al.  Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. , 2019, The Lancet. Oncology.

[30]  N. Socci,et al.  Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.

[31]  G. Fuller,et al.  Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology–morphological and therapeutic implications , 2019, Oncotarget.

[32]  M. Fischer,et al.  Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project , 2019, Pediatric blood & cancer.

[33]  S. Turner,et al.  Opportunities and challenges of circulating biomarkers in neuroblastoma , 2019, Open Biology.

[34]  P. Varlet,et al.  Constitutional mismatch repair deficiency–associated brain tumors: report from the European C4CMMRD consortium , 2019, Neuro-oncology advances.

[35]  C. Ross,et al.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment , 2019, Cardiovascular research.

[36]  D. Pasini,et al.  Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity , 2019, Nature Communications.

[37]  R. Palmer,et al.  Targeting anaplastic lymphoma kinase in neuroblastoma , 2019, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[38]  R. Atun,et al.  Estimating the total incidence of global childhood cancer: a simulation-based analysis. , 2019, The Lancet. Oncology.

[39]  K. Stegmaier,et al.  Ushering in the next generation of precision trials for pediatric cancer , 2019, Science.

[40]  J. Biegel,et al.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment , 2019, Science.

[41]  M. Veening,et al.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. , 2019, The Cochrane database of systematic reviews.

[42]  J. Shay,et al.  Telomeres and telomerase: three decades of progress , 2019, Nature Reviews Genetics.

[43]  Elizabeth A. Sokol,et al.  The Evolution of Risk Classification for Neuroblastoma , 2019, Children.

[44]  A. Ferrari,et al.  Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.

[45]  B. Geoerger,et al.  Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Kristin D. Alfaro,et al.  The molecular landscape of glioma in patients with Neurofibromatosis 1 , 2018, Nature Medicine.

[47]  F. Westermann,et al.  A mechanistic classification of clinical phenotypes in neuroblastoma , 2018, Science.

[48]  Atif A Ahmed,et al.  Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects , 2018, High-throughput.

[49]  Tao Jiang,et al.  Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor , 2018, Cell.

[50]  J. Sicklick,et al.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.

[51]  Xiaotu Ma,et al.  Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome , 2018, Nature Communications.

[52]  Nicholas Light,et al.  Ewing‐like sarcoma: An emerging family of round cell sarcomas , 2018, Journal of cellular physiology.

[53]  Narasimhan P. Agaram,et al.  MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification , 2018, Modern Pathology.

[54]  E. Steliarova-Foucher,et al.  Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study , 2018, The Lancet. Oncology.

[55]  S. Burdach,et al.  Precision medicine in pediatric oncology , 2018, Molecular and Cellular Pediatrics.

[56]  S. Albrecht,et al.  Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency , 2018, Pediatric blood & cancer.

[57]  Darjus F. Tschaharganeh,et al.  The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. , 2018, Cancer cell.

[58]  David T. W. Jones,et al.  Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma , 2018, Nature Communications.

[59]  P. Varlet,et al.  Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis , 2018, Neuro-oncology.

[60]  J. Karlsson,et al.  Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer , 2018, Nature Genetics.

[61]  Roland Eils,et al.  Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort , 2018, The Lancet. Oncology.

[62]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[63]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[64]  H. Lo,et al.  Inhibiting TRK Proteins in Clinical Cancer Therapy , 2018, Cancers.

[65]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[66]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[67]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[68]  Shoma Tsubota,et al.  Origin and initiation mechanisms of neuroblastoma , 2018, Cell and Tissue Research.

[69]  Christopher W Mount,et al.  Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas , 2018, Nature Medicine.

[70]  P. Tan,et al.  Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR–CCNB3 gene fusion , 2018, Histopathology.

[71]  Birgit Geoerger,et al.  Precision medicine in pediatric oncology , 2017, Current opinion in pediatrics.

[72]  James R. Anderson,et al.  Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group , 2017, Pediatric blood & cancer.

[73]  A. Naranjo,et al.  Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group , 2017, Cancer.

[74]  B. Wörmann,et al.  Late Effects and Long-Term Follow-Up after Cancer in Childhood , 2017, Oncology Research and Treatment.

[75]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[76]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[77]  C. Antonescu,et al.  BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas , 2017, The American journal of surgical pathology.

[78]  A. Manabe,et al.  Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors , 2017, Oncoimmunology.

[79]  M. Jongmans,et al.  Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. , 2017, Cancer letters.

[80]  Fang Fang,et al.  Molecular genetics of osteosarcoma. , 2017, Bone.

[81]  Qing-Rong Chen,et al.  A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.

[82]  M. Lim,et al.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  P. Varlet,et al.  Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial , 2017, Clinical Cancer Research.

[84]  M. Snuderl,et al.  Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival , 2017, Journal of Neuro-Oncology.

[85]  K. Savage,et al.  Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma. , 2017, Journal of pediatric hematology/oncology.

[86]  K. Schneider,et al.  Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient , 2017, Clinical Cancer Research.

[87]  N. Cheung,et al.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. , 2017, Cancer treatment reviews.

[88]  M. Loh,et al.  Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies , 2017, Clinical Cancer Research.

[89]  O. Delattre,et al.  Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors , 2017, Pediatric blood & cancer.

[90]  S. Plon,et al.  Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders , 2017, Clinical Cancer Research.

[91]  S. Plon,et al.  Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood , 2017, Clinical Cancer Research.

[92]  D. Fisher,et al.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade , 2017, Cancer.

[93]  S. Pfister,et al.  Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective , 2017, Nature Reviews Clinical Oncology.

[94]  P. Scaffidi,et al.  Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity , 2017, Trends in cancer.

[95]  Yoon-Jae Cho,et al.  Pediatric oncology enters an era of precision medicine. , 2017, Current problems in cancer.

[96]  M. Lim,et al.  Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial , 2017, Journal of the National Cancer Institute.

[97]  R. Pazdur,et al.  FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma , 2017, The oncologist.

[98]  David T. W. Jones,et al.  H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers , 2017, Acta Neuropathologica.

[99]  C. Mackall,et al.  Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. , 2017, Cancer cell.

[100]  A. Chinnaiyan,et al.  Precision medicine in pediatric oncology: Lessons learned and next steps , 2017, Pediatric blood & cancer.

[101]  B. Geoerger,et al.  Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine , 2017, Molecular therapy. Nucleic acids.

[102]  J. Birch,et al.  Factors associated with recurrence and survival length following relapse in patients with neuroblastoma , 2016, British Journal of Cancer.

[103]  A. Borkhardt,et al.  Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  A. Panigrahy,et al.  Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study , 2016, Journal of Neuro-Oncology.

[106]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[107]  M. Frühwald,et al.  Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group. , 2016, Cytotherapy.

[108]  W. D. den Dunnen,et al.  Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas. , 2016, Critical reviews in oncology/hematology.

[109]  A. Panigrahy,et al.  Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. , 2016, Neuro-oncology.

[110]  F. Engert,et al.  Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics , 2016, Oncotarget.

[111]  M. Yalon,et al.  Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors , 2016, Journal of Neuro-Oncology.

[112]  Gudrun Schleiermacher,et al.  Implementation of mechanism of action biology-driven early drug development for children with cancer. , 2016, European journal of cancer.

[113]  David T. W. Jones,et al.  Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.

[114]  U. Dirksen,et al.  Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.

[115]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[116]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[117]  J. Hagenbuchner,et al.  Targeting transcription factors by small compounds--Current strategies and future implications. , 2016, Biochemical pharmacology.

[118]  Roland Eils,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[119]  R. Lulla,et al.  Mutations in chromatin machinery and pediatric high-grade glioma , 2016, Science Advances.

[120]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[121]  K. Kawa,et al.  Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children , 2016, Pediatric blood & cancer.

[122]  R. Carpenter,et al.  Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors , 2016, Cancers.

[123]  M. Fischer,et al.  Telomere maintenance is pivotal for high-risk neuroblastoma , 2016, Cell cycle.

[124]  S. Steinberg,et al.  Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas , 2016, Clinical Cancer Research.

[125]  Nathan C. Sheffield,et al.  The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease , 2016, Oncotarget.

[126]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[127]  P. Nathan,et al.  Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. , 2016, The New England journal of medicine.

[128]  M. McVey,et al.  Error‐Prone Repair of DNA Double‐Strand Breaks , 2016, Journal of cellular physiology.

[129]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[130]  E. Hiyama,et al.  Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. , 2015, Journal of pediatric surgery.

[131]  D. Wheeler,et al.  Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney , 2015, Nature Communications.

[132]  J. Wolchok,et al.  Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[133]  D. Zwijnenburg,et al.  Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors , 2016 .

[134]  Simon C Watkins,et al.  Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.

[135]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[137]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[138]  Michael C. Rusch,et al.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  A. Look,et al.  Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study , 2015, British Journal of Cancer.

[140]  S. Wootton-Gorges,et al.  Malignant renal tumors in children , 2015, Journal of kidney cancer and VHL.

[141]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[142]  Mads Thomassen,et al.  Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. , 2015, JAMA.

[143]  J. Soulier,et al.  Fanconi anemia and solid malignancies in childhood: A national retrospective study , 2015, Pediatric blood & cancer.

[144]  Eckart Meese,et al.  Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. , 2015, Cancer cell.

[145]  J. Blay,et al.  Detection of tumor ALK status in neuroblastoma patients using peripheral blood , 2015, Cancer medicine.

[146]  C. Allis,et al.  Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation , 2014, Science.

[147]  R. Reddel.  Telomere Maintenance Mechanisms in Cancer: Clinical Implications , 2014, Current pharmaceutical design.

[148]  Ravi Radhakrishnan,et al.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.

[149]  Chris Jones,et al.  Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.

[150]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[151]  F. Speleman,et al.  Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  F. Barkhof,et al.  Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. , 2014, Neuro-oncology.

[153]  KyungMann Kim,et al.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  N. Wadhwa.  Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors , 2014, Indian journal of orthopaedics.

[155]  A. Duval,et al.  Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘Care for CMMRD’ (C4CMMRD) , 2014, Journal of Medical Genetics.

[156]  I. Smith,et al.  Status of adjuvant endocrine therapy for breast cancer , 2014, Breast Cancer Research.

[157]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[158]  J. Kilday,et al.  Targeted Therapy in Pediatric Low-Grade Glioma , 2014, Current Neurology and Neuroscience Reports.

[159]  C. Hawkins,et al.  Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. , 2014, European journal of cancer.

[160]  A. Duval,et al.  Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D) , 2014, Journal of Medical Genetics.

[161]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[162]  C. Fletcher.  The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification , 2014, Histopathology.

[163]  M. Hudson,et al.  Survivors of childhood and adolescent cancer: life-long risks and responsibilities , 2013, Nature Reviews Cancer.

[164]  David T. W. Jones,et al.  Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.

[165]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[166]  T. Curran,et al.  Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study , 2013, Clinical Cancer Research.

[167]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[168]  James R. Anderson,et al.  PAX‐FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report , 2013, Pediatric blood & cancer.

[169]  John Anderson,et al.  New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK , 2013, Clinical Cancer Research.

[170]  A. Baruchel,et al.  A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. , 2013, European journal of cancer.

[171]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[172]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[173]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[174]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[175]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[176]  Xavier Paoletti,et al.  Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents , 2012, PloS one.

[177]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[178]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in inherited disease , 2012, Clinical Sarcoma Research.

[179]  A. Oberthuer,et al.  Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma , 2012, Journal of Human Genetics.

[180]  Bandana Sharma,et al.  The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. , 2012, Cancer cell.

[181]  Puja Gupta,et al.  Late effects in adult survivors of pediatric cancer: a guide for the primary care physician. , 2012, The American journal of medicine.

[182]  Damien C Weber,et al.  Epidemiology of glial and non-glial brain tumours in Europe. , 2012, European journal of cancer.

[183]  Mauro Delorenzi,et al.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[185]  M. Ladanyi,et al.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. , 2012, Annual review of pathology.

[186]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[187]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[188]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[189]  T. MacDonald,et al.  Treatment of high-grade glioma in children and adolescents. , 2011, Neuro-oncology.

[190]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[191]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  N. Alon,et al.  BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma , 2011, Clinical Cancer Research.

[193]  W. Winkelmann,et al.  The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[194]  B. Porter,et al.  Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update , 2011, Current treatment options in neurology.

[195]  J. Biegel,et al.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors , 2011, Pediatric blood & cancer.

[196]  M. Mathieu,et al.  Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome , 2010, Radiation oncology.

[197]  R. Reddel,et al.  Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers , 2010, FEBS letters.

[198]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[199]  K. Schaefer,et al.  Prognostic value of PAX–FKHR fusion status in alveolar rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma study group (CWS) , 2010, Pediatric blood & cancer.

[200]  P. Kearns,et al.  The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. , 2010, Cancer treatment reviews.

[201]  Xavier Paoletti,et al.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents , 2010, Targeted Oncology.

[202]  R. Siebert,et al.  Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.

[203]  R. Siebert,et al.  Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor , 2010, Genes, chromosomes & cancer.

[204]  R. Kleinerman.  Radiation-sensitive genetically susceptible pediatric sub-populations , 2009, Pediatric Radiology.

[205]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[206]  C. Linardic.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma. , 2008, Cancer letters.

[207]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[208]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[209]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[210]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[212]  B. Geoerger,et al.  Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors. , 2008, Current cancer drug targets.

[213]  Jeffrey S Barrett,et al.  Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  N. Thomas,et al.  Germline and somatic NF1 gene mutation spectrum in NF1‐associated malignant peripheral nerve sheath tumors (MPNSTs) , 2008, Human mutation.

[215]  Jörg Breitkreutz,et al.  Paediatric and geriatric drug delivery , 2007, Expert opinion on drug delivery.

[216]  A. D’Andrea,et al.  DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[217]  S. Lipshultz.  Exposure to anthracyclines during childhood causes cardiac injury. , 2006, Seminars in oncology.

[218]  G. Siegal,et al.  Osteosarcoma: anatomic and histologic variants. , 2006, American journal of clinical pathology.

[219]  P. Adamson,et al.  Pediatric phase I trials in oncology: an analysis of study conduct efficiency. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. , 2002, Cancer genetics and cytogenetics.

[222]  F. Barr.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma , 2001, Oncogene.

[223]  T. Jacks,et al.  NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.

[224]  B. Scheithauer,et al.  Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex , 1998, Cancer.

[225]  R. Myers,et al.  Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.

[226]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[227]  J. Downing,et al.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. , 1993, Cancer research.

[228]  B. Emanuel,et al.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[229]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[230]  Analysis at Eight Years by 'Nolvadex',et al.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. , 1988, British Journal of Cancer.

[231]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.

[232]  Int Guideline Harmonization Grp.  Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium , 2019 .

[233]  B. Pawel.  SMARCB1-deficient Tumors of Childhood: A Practical Guide , 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[234]  M. Fischer,et al.  Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. , 2017, Oncotarget.

[235]  Y. Taniguchi.  The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins , 2016, International journal of molecular sciences.

[236]  P. Crino,et al.  Genetics of tuberous sclerosis complex : implications for clinical practice , 2016 .

[237]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[238]  M. Schrappe,et al.  Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. , 2015, European journal of cancer.

[239]  H. Wakimoto,et al.  Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. , 2015, Science.

[240]  David Hogg,et al.  Mutations in SUFU predispose to medulloblastoma , 2002, Nature Genetics.

[241]  D. Long.  Non-glial tumors of the brain: tumors of the cerebellopontine angle and meningiomas. , 1992, Current opinion in neurology and neurosurgery.